Our monoclonal antibodies are designed to target novel epitopes for optimized interaction with their target receptors. This can facilitate precise engagement between the desired immune effector cells and modulation of the target signaling pathways. Antibodies targeting different epitopes compared to benchmark antibodies may engage distinct immune cell populations, such as different subsets of T cells, or NK cells, leading to a broader and more robust anti-tumor immune response compared to benchmark antibodies in multiple disease models.
